Skip to main content

Bulletin from Moberg Pharma´s Extraordinary General Meeting on August 8, 2023

STOCKHOLM, 8 August 2023. Moberg Pharma AB (publ)’s (OMX: MOB) (the “Company”) Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved as set out below.

Resolution to amend the Articles of Association
The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to amend the limits for the share capital in the Articles of Association to not less than SEK 15,000,000 and not more than SEK 60,000,000 (previously not less than SEK 10,000,000 and not more than SEK 40,000,000) and to amend the limits for the number of shares to not less than 15,000,000 and not more than 60,000,000 (previously not less than 10,000,000 and not more than 40,000,000).

Approval of the Board of Directors' decision on rights issue
The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution on 28 June 2023 on a new issue of units consisting of ordinary shares and warrants of series 2023:1 with preferential rights for the current shareholders in the Company. According to the terms for the rights issue determined by the Board of Directors, as announced on 7 August 2023, each share in the Company held on the record date for participation in the rights issue, 14 August 2023, entitles to sixteen (16) unit rights and nine (9) unit rights entitle to subscription for one (1) unit.[1] In total, up to 17,470,149 units may be issued, whereby each unit consists of one ordinary share and one warrant of series 2023:1. This means that a maximum of 17,470,149 ordinary shares and a maximum of 17,470,149 warrants of series 2023:1 will be issued in the rights issue. Through the issuance of the new ordinary shares in the rights issue, the Company's share capital will increase by a maximum of SEK 17,470,149.867306. If all warrants of series 2023:1 are exercised for subscription of new ordinary shares, the share capital will increase by an additional maximum of SEK 17,470,149.867306.

The subscription price is SEK 5.75 per unit. This means that the subscription price for each new ordinary share is SEK 5.75 as the warrants are issued free of charge. The Company is expected to receive issue proceeds of a maximum of approximately SEK 100 million before transaction costs. In the event that the warrants are exercised for subscription of new ordinary shares, the Company will receive additional issue proceeds in June 2024. The subscription period will run during the period 16 August 2023 – 30 August 2023. Additional information regarding the rights issue will be included in the prospectus which will be published prior to the subscription period.

For additional information, please contact:
Anna Ljung, CEO, telephone: 070 - 766 60 30, e-mail:
Mark Beveridge, VP Finance, telephone: 076 - 805 82 88, e-mail:

About this information
The information was submitted for publication, through the agency of the contact persons set out above, at 4:00 pm CEST on 8 August 2023.

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).

[1] Excluding treasury shares. As of 8 August 2023, Moberg Pharma holds 445,974 ordinary shares, which do not entitle to participation in the rights issue.